The global DNA Probe-based Diagnostic Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Direct Detection of Target Sequence, Nucleic Acid Amplification, Gene Detection Using DNA Chips, Gene Detection By DNA Sequencing), By Application (Infectious disease testing, Cancer testing).
The DNA Probe-based Diagnostic Market focuses on molecular diagnostic assays and testing methods that utilize DNA probes to detect specific genetic sequences, mutations, pathogens, and biomarkers associated with diseases, infections, and genetic disorders. DNA probe-based diagnostics employ techniques like fluorescence in situ hybridization (FISH), Southern blotting, and nucleic acid amplification to identify and quantify target DNA or RNA sequences in clinical samples. Widely used in medical laboratories, research institutions, and healthcare settings, DNA probe-based diagnostics offer rapid, sensitive, and accurate results for personalized medicine, infectious disease diagnosis, and genetic screening.
The global DNA Probe-based Diagnostic Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, DNA Probe-based Diagnostic Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the DNA Probe-based Diagnostic Industry include- Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann La Roche, GE Healthcare, Thermo Fisher Scientific Inc.
One Market Trend in DNA probe-based diagnostics is the increasing adoption of molecular diagnostics for infectious disease testing. DNA probe-based assays, including nucleic acid amplification tests (NAATs) and hybridization-based assays, are widely used for the rapid and accurate detection of pathogens such as bacteria, viruses, and fungi in clinical specimens. With advancements in molecular biology techniques and the availability of automated platforms, DNA probe-based diagnostics offer high sensitivity, specificity, and throughput for detecting infectious agents, aiding in the timely diagnosis and management of infectious diseases. This trend is driven by the growing global burden of infectious diseases, including emerging pathogens, antimicrobial resistance, and healthcare-associated infections, necessitating the use of sensitive and specific diagnostic tests for disease surveillance, outbreak investigation, and patient care.
The driver behind the demand for DNA probe-based diagnostics is the increasing need for point-of-care testing and decentralized diagnostic solutions in healthcare settings. Point-of-care molecular diagnostics offer rapid turnaround times, on-site testing capabilities, and actionable results at the patient's bedside or in remote settings, enabling timely clinical decision-making, infection control measures, and antimicrobial stewardship interventions. DNA probe-based assays integrated into portable, easy-to-use platforms allow healthcare providers to perform nucleic acid testing outside of traditional laboratory settings, including emergency departments, ambulatory care clinics, and resource-limited settings where access to centralized laboratory facilities may be limited. Furthermore, the COVID-19 pandemic has underscored the importance of point-of-care molecular testing for respiratory infections, driving the development and adoption of rapid DNA probe-based assays for SARS-CoV-2 detection in community healthcare settings, workplaces, and public health screening programs.
An opportunity exists for manufacturers of DNA probe-based diagnostics to develop multiplexed assays capable of simultaneously detecting multiple pathogens in a single test, addressing the need for comprehensive infectious disease testing and differential diagnosis. Multiplexed assays offer advantages such as increased testing efficiency, reduced turnaround times, and improved resource utilization by allowing for the detection of multiple targets within a single clinical specimen. By leveraging multiplex PCR, microarray-based technologies, or next-generation sequencing (NGS) platforms, manufacturers can design assays targeting a panel of clinically relevant pathogens associated with specific syndromes or disease presentations, such as respiratory tract infections, bloodstream infections, or gastrointestinal illnesses. Additionally, multiplexed assays enable syndromic testing for emerging infectious diseases, bioterrorism agents, or antimicrobial-resistant pathogens, facilitating early detection and response to public health threats and reducing the burden on healthcare systems. By investing in the development of multiplexed DNA probe-based assays, manufacturers can address the evolving needs of healthcare providers for comprehensive infectious disease diagnostics, enhance patient care outcomes, and contribute to the global efforts to combat infectious disease outbreaks and antimicrobial resistance.
Within DNA probe-based diagnostics, nucleic acid amplification techniques are experiencing the most rapid growth. Nucleic acid amplification methods, such as polymerase chain reaction (PCR) and its variants, enable the rapid and sensitive detection of target sequences within a sample by amplifying specific regions of DNA or RNA. This technology has revolutionized infectious disease testing and cancer testing by allowing for the detection of pathogens or cancer biomarkers with high specificity and sensitivity. The surge in demand for nucleic acid amplification can be attributed to its versatility, efficiency, and accuracy in diagnosing various diseases. Additionally, the ongoing COVID-19 pandemic has highlighted the importance of nucleic acid amplification techniques in diagnosing viral infections, driving further adoption and innovation in this field. As healthcare providers strive for more accurate and timely diagnostic solutions, nucleic acid amplification is expected to continue its rapid growth, playing a pivotal role in advancing molecular diagnostics and improving patient outcomes.
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Abbott Laboratories
Becton, Dickinson and Company
F. Hoffmann La Roche
GE Healthcare
Thermo Fisher Scientific Inc
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the DNA Probe-based Diagnostic Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the DNA Probe-based Diagnostic Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 DNA Probe-based Diagnostic Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global DNA Probe-based Diagnostic Market Size Outlook, $ Million, 2021 to 2030
3.2 DNA Probe-based Diagnostic Market Outlook by Type, $ Million, 2021 to 2030
3.3 DNA Probe-based Diagnostic Market Outlook by Product, $ Million, 2021 to 2030
3.4 DNA Probe-based Diagnostic Market Outlook by Application, $ Million, 2021 to 2030
3.5 DNA Probe-based Diagnostic Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of DNA Probe-based Diagnostic Industry
4.2 Key Market Trends in DNA Probe-based Diagnostic Industry
4.3 Potential Opportunities in DNA Probe-based Diagnostic Industry
4.4 Key Challenges in DNA Probe-based Diagnostic Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global DNA Probe-based Diagnostic Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global DNA Probe-based Diagnostic Market Outlook by Segments
7.1 DNA Probe-based Diagnostic Market Outlook by Segments, $ Million, 2021- 2030
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
8 North America DNA Probe-based Diagnostic Market Analysis and Outlook To 2030
8.1 Introduction to North America DNA Probe-based Diagnostic Markets in 2024
8.2 North America DNA Probe-based Diagnostic Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America DNA Probe-based Diagnostic Market size Outlook by Segments, 2021-2030
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
9 Europe DNA Probe-based Diagnostic Market Analysis and Outlook To 2030
9.1 Introduction to Europe DNA Probe-based Diagnostic Markets in 2024
9.2 Europe DNA Probe-based Diagnostic Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe DNA Probe-based Diagnostic Market Size Outlook by Segments, 2021-2030
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
10 Asia Pacific DNA Probe-based Diagnostic Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific DNA Probe-based Diagnostic Markets in 2024
10.2 Asia Pacific DNA Probe-based Diagnostic Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific DNA Probe-based Diagnostic Market size Outlook by Segments, 2021-2030
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
11 South America DNA Probe-based Diagnostic Market Analysis and Outlook To 2030
11.1 Introduction to South America DNA Probe-based Diagnostic Markets in 2024
11.2 South America DNA Probe-based Diagnostic Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America DNA Probe-based Diagnostic Market size Outlook by Segments, 2021-2030
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
12 Middle East and Africa DNA Probe-based Diagnostic Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa DNA Probe-based Diagnostic Markets in 2024
12.2 Middle East and Africa DNA Probe-based Diagnostic Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa DNA Probe-based Diagnostic Market size Outlook by Segments, 2021-2030
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Becton, Dickinson and Company
F. Hoffmann La Roche
GE Healthcare
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Direct Detection of Target Sequence
Nucleic Acid Amplification
Gene Detection Using DNA Chips
Gene Detection By DNA Sequencing
By Application
Infectious disease testing
Cancer testing
The global DNA Probe-based Diagnostic Market is one of the lucrative growth markets, poised to register a 5.4% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann La Roche, GE Healthcare, Thermo Fisher Scientific Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume